AbbVie Submits Applications for Upadacitinib (RINVOQ) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines...

Mount Carmel Register

Jan 7, 2022

AbbVie Submits Applications for Upadacitinib (RINVOQ) in Non-Radiographic Axial Spondyloarthritis to U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) |!|…